4D Molecular Therapeutics Inc Contracts & Agreements
44 Contracts & Agreements
- Business Finance (12 contracts)
- Business Operations (5)
- Human Resources (17)
- Intellectual Property (5)
- Uncategorized (5)
- Form of Pre-Funded Warrant issued in conjunction with December 2024 exchange (Filed With SEC on December 11, 2024)
- Form of Pre-Funded Warrant issued in conjunction with November 2024 exchange (Filed With SEC on November 13, 2024)
- Sales Agreement, dated June 7, 2024, by and between the Company and Leerink Partners LLC (Filed With SEC on June 7, 2024)
- Amended and Restated Change in Control and Severance Agreement, dated June 23, 2023 by and between Robert Kim and the Registrant (Filed With SEC on February 29, 2024)
- Change in Control and Severance Agreement, dated September 22, 2021, by and between Scott Bizily and the Registrant (Filed With SEC on February 29, 2024)
- Change in Control and Severance Agreement, dated August 29, 2023, by and between Uneek Mehra and the Registrant (Filed With SEC on February 29, 2024)
- Offer Letter, dated September 4, 2023, between Uneek Mehra and the Registrant (Filed With SEC on February 29, 2024)
- Form of Pre-Funded Warrant (Filed With SEC on February 9, 2024)
- Underwriting Agreement, dated as of February 6, 2024, among 4D Molecular Therapeutics, Inc. and Goldman Sachs & Co. LLC, BofA Securities, Inc., Jefferies LLC and Barclays Capital... (Filed With SEC on February 9, 2024)
- License Agreement between the Registrant and Astellas Gene Therapies, Inc., dated as of July 5, 2023 (Filed With SEC on November 9, 2023)
- Underwriting Agreement, dated as of May 4, 2023, among 4D Molecular Therapeutics, Inc. and Goldman Sachs & Co. LLC, BofA Securities, Inc. and Evercore Group, L.L.C (Filed With SEC on May 9, 2023)
- Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on May 12, 2022)
- Description of Securities of the Registrant (Filed With SEC on March 28, 2022)
- Change in Control and Severance Agreement, dated September 22, 2021, by and between Fred Kamal and 4D Molecular Therapeutics, Inc (Filed With SEC on November 10, 2021)
- Form of Underwriting Agreement (Filed With SEC on October 26, 2021)
- Change in Control and Severance Agreement, dated September 22, 2021, by and between Robert Stephen Fishman and 4D Molecular Therapeutics, Inc (Filed With SEC on September 24, 2021)
- Change in Control and Severance Agreement, dated September 22, 2021, by and between August Moretti and 4D Molecular Therapeutics, Inc (Filed With SEC on September 24, 2021)
- Change in Control and Severance Agreement, dated September 22, 2021, by and between David Kirn and 4D Molecular Therapeutics, Inc (Filed With SEC on September 24, 2021)
- Description of Securities of the Registrant (Filed With SEC on March 25, 2021)
- Offer Letter, dated March 20, 2015 between David Kirn, M.D. and the Registrant (Filed With SEC on December 7, 2020)
- Offer Letter, dated January 4, 2019 between August Moretti and the Registrant (Filed With SEC on December 7, 2020)
- Employment Agreement, dated January 15, 2019 between Peter Francis, M.D., Ph.D. and the Registrant (Filed With SEC on December 7, 2020)
- Exclusive License and Bailment Agreement, dated December 19, 2013, between the Registrant and The Regents of the University of California (Filed With SEC on December 7, 2020)
- Form of Underwriting Agreement (Filed With SEC on December 7, 2020)
- Form of Common Stock Certificate (Filed With SEC on December 7, 2020)
- Amended and Restated Investors Rights Agreement, dated as of April 29, 2020, among the Registrant and the investors party thereto (Filed With SEC on December 7, 2020)
- 2020 Incentive Award Plan (Filed With SEC on December 7, 2020)
- Form of Stock Option Grant Notice and Stock Option Agreement under the 2020 Incentive Award Plan (Filed With SEC on December 7, 2020)
- Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2020 Incentive Award Plan (Filed With SEC on December 7, 2020)
- Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2020 Incentive Award Plan (Filed With SEC on December 7, 2020)
- 2020 Employee Stock Purchase Plan (Filed With SEC on December 7, 2020)
- Form of Indemnification Agreement for directors and officers (Filed With SEC on December 7, 2020)
- Exclusive License and Bailment Agreement, dated December 19, 2013, between the Registrant and The Regents of the University of California (Filed With SEC on December 7, 2020)
- Exclusive License and Bailment Agreement, dated December 19, 2013, between the Registrant and The Regents of the University of California (Filed With SEC on November 17, 2020)
- Exclusive License and Bailment Agreement, dated December 19, 2013, between the Registrant and The Regents of the University of California (Filed With SEC on November 17, 2020)
- Collaboration and License Agreement, dated August 6, 2019, by and between the Registrant and uniQure biopharma B.V (Filed With SEC on November 17, 2020)
- Amended and Restated Collaboration and License Agreement, dated August 6, 2019, between the Registrant and uniQure biopharma B.V (Filed With SEC on November 17, 2020)
- Collaboration and License Agreement, dated November 16, 2017, among the Registrant, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc (Filed With SEC on November 17, 2020)
- Form of Stock Option Agreement under 2015 Equity Incentive Plan (Filed With SEC on November 17, 2020)
- 2015 Equity Incentive Plan (Filed With SEC on November 17, 2020)
- Amended and Restated Investors Rights Agreement, dated as of April 29, 2020, among the Registrant and the investors party thereto (Filed With SEC on November 17, 2020)
- Amended and Restated Investors Rights Agreement, dated as of August 27, 2018, among the Registrant and the investors party thereto (Filed With SEC on September 30, 2019)
- Form of Stock Option Agreement under 2015 Equity Incentive Plan (Filed With SEC on September 30, 2019)
- 2015 Equity Incentive Plan (Filed With SEC on September 30, 2019)
